Home · Health · Sep 25 archive
IBD Onset May Occur Long Before Patients Are Symptomatic
Confirmed
In Short: A recent study published in Medscape suggests that the onset of inflammatory bowel disease (IBD) may occur long before patients become symptomatic.
Mehandru and colleagues discovered that a novel autoantibody, anti-avb6, can be detected before the onset of ulcerative colitis (UC).
In patients who later developed Crohn's disease (CD), the study found elevated herpesvirus-directed responses, particularly Epstein-Barr virus (EBV), and anti-flagellin antibodies up to 10 years before diagnosis.
The researchers conducted large-scale serologic profiling of archived prediagnostic samples, identifying disease-specific immune trajectories years before IBD onset.
These incipient immune signatures of future IBD, silently underway, may be detectable through broad serologic testing as far back as 10 years before diagnosis.
This finding offers new insights into the disease’s prodromal phase and a potential path toward earlier identification of high-risk patients.
The researchers noted that their findings could help clinicians identify patients at risk of developing IBD much earlier, potentially leading to earlier intervention and better outcomes.
What this adds
The study highlights the importance of broad serologic testing in identifying early immune signatures of IBD.
What's confirmed
- Mehandru and colleagues discovered that a novel autoantibody, anti-avb6, can be detected before the onset of ulcerative colitis (UC).
- In patients who later developed Crohn's disease (CD), the study found elevated herpesvirus-directed responses, particularly Epstein-Barr virus (EBV), and anti-flagellin antibodies up to 10 years before diagnosis.
- The researchers conducted large-scale serologic profiling of archived prediagnostic samples, identifying disease-specific immune trajectories years before IBD onset.
- These incipient immune signatures of future IBD, silently underway, may be detectable through broad serologic testing as far back as 10 years before diagnosis.
- This finding offers new insights into the disease’s prodromal phase and a potential path toward earlier identification of high-risk patients.
- The researchers noted that their findings could help clinicians identify patients at risk of developing IBD much earlier, potentially leading to earlier intervention and better outcomes.
What's still developing
- The onset of inflammatory bowel disease (IBD) may occur long before patients become symptomatic, according to a recent study.
- Republican Sen. Roger Marshall (Kansas) sued hundreds of his patients for outstanding debts and had dozens of them arrested over the course of his decades-long career as an obstetrician-gynecologist, new reporting reveals.
- Court records show that Marshall, who is running for reelection this fall, sued over 700 of his patients for debts.
- Many patients who Marshall’s office sued were new parents who had just given birth and were stuck with the delivery bill.
- And, in 81 cases, patients were arrested for missing court dates in relation to their debts — though several people interviewed by the Times said they were never notified about the court dates to begin with.
- Roger Marshall served many patients in a poor, rural part of his state.
- His practice, which he owned for over two decades, placed an 18 percent interest rate on bills for many patients — even as it served a rural area of Kansas that had a high proportion of poor and uninsured patients, for whom Marshall’s practice was the only option in the area.
- Not long ago, discovering a new drug followed a familiar, painstaking arc.
- Scientists would spend years identifying a biological target, screening thousands of compounds and refining promising leads in the lab — often with no guarantee that this effort would ultimately benefit patients.
- A major trial found that implantable cardioverter-defibrillators may benefit some patients younger than 70 with mild-to-moderate heart dysfunction and cardiac scarring.
- A more than decade-long randomized trial suggests that implantable cardioverter-defibrillators may benefit some patients who have heart scarring and only mild-to-moderate loss of heart function, a group that currently falls outside standard treatment guidelines.
- Although the devices did not significantly reduce the trial’s primary endpoint across all age groups, a prespecified analysis found a significant reduction among patients younger than 70, while sudden cardiac death was also reduced as a secondary endpoint across the full study group.